{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-25-000022","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.755908+00:00","generated_at":"2026-05-22T04:17:06.084486+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Prothena Q1 net loss $60.2M, cash $418.8M; AFFIRM-AL data due Q2 2025","bullets":["Net loss $60.2M ($1.12/share) vs $72.2M ($1.34/share) year ago; revenue $2.8M (from BMS collaboration).","Cash $418.8M at quarter end; FY2025 net cash burn guidance $168-175M, ending cash ~$301M.","Phase 3 AFFIRM-AL (birtamimab) topline results expected Q2 2025; SPA with FDA, primary endpoint all-cause mortality.","Multiple PRX012 Phase 1 readouts expected from mid-2025; Roche to decide prasinezumab next steps mid-year.","Novo Nordisk's coramitug Phase 2 for ATTR-CM completes enrollment; results expected H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-25-000022","json":"https://secwatch.observer/filing/0001559053-25-000022.json","markdown":"https://secwatch.observer/filing/0001559053-25-000022.md","text":"https://secwatch.observer/filing/0001559053-25-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905325000022/0001559053-25-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905325000022/prta-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:17:06.084486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}